雷米普利降低高血压患者心房颤动发生率以及改善左心房内径临床观察  

Ramipri in lowering incidence of atrial fibrillation and in improving internal diameter of left atrium.

作　　者：张大勇[1] 李德才[1] 蒋涛[1] 王庆旭[1] 刘思泰[1] 唐焕君[1] 舒艳[1] 

机构地区：[1]川北医学院第二附属医院心内科,四川省绵阳市621000

出　　处：《中国医药》2007年第3期141-142,共2页China Medicine

摘　　要：目的 观察血管紧张素转换酶抑制剂（ACEI）雷米普利降低高血压患者心房颤动（AF）发生率及对左心房内径的影响。方法 将180例原发性高血压患者分为治疗组（90例）和对照组（90例）。治疗组给予雷米普利（2．5～15）mg／d口服，连服50个月。对照组苯磺碳氨氯地平（2．5～10）mg／d口服，连服50个月。结果 治疗50个月后治疗组AF发生率3．4％，对照组AF发生率为8．05％；治疗组左心房内径缩小（2．0±1．5）mm，对照组左心房内径缩小（0．0±1．6）mm。2组相对比P〈0．05，有统计学意义。结论 雷米普利可降低高血压患者AF的发生率并缩小左心房内径。Objective To observe the effect of ramipril on the incidence of atrial fibrillation （AF） and internal diameter of left atrium. Methods One hundred and eighty cases of essential hypertension were divided into ramipril group and amlodipine besylate tablet group（control group） （ n = 90 for each group）. Ramipril group orally administrated 2.5 mg-15 mg/d ramipril for 50 months while amlodipine besylate tablet group administrated 2.5-10 mg/d amlodipine besylate tablet for 50 months. Results The incidence of AF was 3.4% and 8.05% while the internal diameter of left atrium was shortened by （ 2.0 ± 1.5 ）mm and （ 0 ± 1.6 ） mm in ramipril group and control group 50 months after treatment, respectively （ P 〈 0.05 ）. Conclusion Ramipril may reduce the incidence of AF and decrease the internal diameter of left atrium of essential hypertension patients.

关 键 词：高血压 雷米普利 心房颤动 左心房内径 

分 类 号：R544.1[医药卫生—心血管疾病]